Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 1307Carcinoma, Renal Cell 660Urinary Bladder Neoplasms 405Carcinoma, Non-Small-Cell Lung 333Neoplasms 301Carcinoma, Transitional Cell 263Breast Neoplasms 252Ovarian Neoplasms 248Melanoma 235Colorectal Neoplasms 227Neoplasm Metastasis 214Kidney Neoplasms 200Pancreatic Neoplasms 169Stomach Neoplasms 162Squamous Cell Carcinoma of Head and Neck 143Lung Neoplasms 140Uterine Cervical Neoplasms 123Non-Muscle Invasive Bladder Neoplasms 118Triple Negative Breast Neoplasms 112Head and Neck Neoplasms 111Endometrial Neoplasms 109Esophageal Neoplasms 107Carcinoma, Hepatocellular 97Small Cell Lung Carcinoma 80Sarcoma 75Colonic Neoplasms 55Urologic Neoplasms 53Prostatic Neoplasms, Castration-Resistant 47Liver Neoplasms 47Cholangiocarcinoma 43

Interventions

cediranib 1Leuprolide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Prostate Adenocarcinoma × Genitourinary × Clear all
NCT04914195 2023-08-01

Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer

Bharat Serums and Vaccines Limited

Phase 3 Completed
155 enrolled
Genitourinary

Advanced Prostate Adenocarcinoma

NCT04843319 2023-05-19

VERU-100

Veru Inc.

Phase 1/2 Terminated
24 enrolled
Genitourinary

Advanced Prostate Adenocarcinoma

NCT00502164 2011-01-21

AZD2171IL/0003

AstraZeneca

Phase 1 Completed
40 enrolled
Genitourinary

Advanced Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡